PTCT
PTC Therapeutics Inc
NASDAQ: PTCT · HEALTHCARE · BIOTECHNOLOGY
$76.85
+0.47% today
Updated 2026-06-05
Market cap
$6.23B
P/E ratio
—
P/S ratio
7.54x
EPS (TTM)
$-2.54
Dividend yield
—
52W range
$43 – $88
Volume
1.2M
WallStSmart proprietary scores
38
out of 100
Grade: D
Sell
Investment rating
5.3
Growth
C+6.5
Quality
B3.5
Profitability
D6.0
Valuation
B5/9
Piotroski F-Score
Moderate
0.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$88.36
+14.98%
12-Month target
$64.52
-16.04%
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy6 Buy3 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity -2.19x — low leverage
Risks
- Altman Z 0.67 — distress zone
- Thin margins at -22.60%
- Negative free cash flow $-60.24M
- Revenue declining -76.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $698.80M | $937.82M | $806.78M | $1.73B | $827.11M | $1.1B |
| Net income | $-559.02M | $-626.60M | $-363.30M | $682.64M | $-2.81M | — |
| EPS | — | — | — | — | $-2.54 | $-0.15 |
| Free cash flow | $-509.11M | $-279.04M | $-181.94M | $702.34M | $-60.24M | — |
| Profit margin | -80.00% | -66.81% | -45.03% | 39.44% | -22.60% | — |
Peer comparison
Smart narrative
PTC Therapeutics Inc trades at $76.85. Our Smart Value Score of 38/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.67, it sits in the distress. TTM revenue stands at $827.11M. with profit margins at -22.60%.
Frequently asked questions
What is PTC Therapeutics Inc's stock price?
PTC Therapeutics Inc (PTCT) trades at $76.85, on a P/S of 7.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is PTC Therapeutics Inc overvalued?
PTC Therapeutics Inc carries a Smart Value Score of 38/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of PTC Therapeutics Inc (PTCT)?
The 12-month analyst consensus target is $88.36, about 15.0% above the current $76.85. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of PTCT by 2030?
Our research-backed model puts the 2030 base case at $49.91, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is PTC Therapeutics Inc's revenue?
PTC Therapeutics Inc's trailing twelve-month revenue is $827.11M, and our model projects it reaching about $2.58B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
PTC Therapeutics Inc's Altman Z-Score is 0.67, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.54x
ROE-7,740.00%
Beta0.55
50D MA$70.42
200D MA$69.76
Shares out0.08B
Float0.07B
Short ratio—
Avg volume1.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—